• Estradiol Benzoate: Optimizing Estrogen Receptor Signaling R

  2026-07-30

  Estradiol Benzoate stands out as a high-purity, potent estrogen receptor alpha agonist, enabling reproducible hormone receptor binding assays and advanced pathway dissection. This article delivers actionable protocols, troubleshooting insights, and strategic comparisons—empowering researchers to achieve precision in estrogen receptor-mediated signaling studies using the APExBIO standard.

• Mono-ADP-Ribosylation Marks PARP7 and AHR for Protein Degrad

  2026-07-30

  This study reveals that mono-ADP-ribosylation acts as an endogenous degradation signal for PARP7, AHR, and their substrates, mediated by the E3 ligase DTX2. By blocking the ubiquitin pathway, the authors provide new mechanistic insights into protein turnover and transcriptional regulation, with implications for cancer research and cell stress pathway studies.

• AICAR Phosphate (Acadesine): AMPK Activation and Apoptosis i

  2026-07-29

  AICAR phosphate (Acadesine) is a potent AMPK activator shown to induce apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. It acts via caspase activation and mitochondrial cytochrome c release, with selectivity for B cells over T cells. This article reviews mechanistic insights, quantitative benchmarks, and practical parameters relevant for cancer research and cell signaling studies.

• Structure-Based Screening Reveals NSP15 Inhibitors in SARS-C

  2026-07-29

  This study innovatively applies structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of SARS-CoV-2 NSP15, a key viral endoribonuclease involved in immune evasion. The findings demonstrate the feasibility of targeting NSP15 to reduce viral virulence, highlighting new avenues for antiviral drug development.

• Bestatin (Ubenimex): Reliable Aminopeptidase Inhibition for

  2026-07-28

  This article provides practical, scenario-driven guidance for researchers using Bestatin (Ubenimex) (SKU A2575) in cell viability, proliferation, and multidrug resistance assays. By analyzing common challenges in assay reproducibility and data interpretation, we demonstrate how SKU A2575 delivers consistent inhibition, reliable performance, and workflow compatibility, all rooted in published data and best practices.

• Dual-Action p38α MAPK Inhibitors Promote Dephosphorylation

  2026-07-28

  The referenced study demonstrates that select p38α MAPK inhibitors not only inhibit kinase catalytic activity but also promote dephosphorylation of the activation loop by stabilizing a phosphatase-accessible conformation. This dual-action mechanism offers a new paradigm for designing more specific and effective kinase-targeted interventions, with direct implications for research into inflammation and related signaling pathways.

• NLRP3 Inflammasome Drives Astrocyte Changes in Morphine Tole

  2026-07-27

  Yuan et al. reveal that NLRP3 inflammasome activation is a key driver of neurotoxic astrocyte phenotype transformation in the development of morphine tolerance. Their work demonstrates that selective NLRP3 inhibition—using agents such as MCC950 sodium—can reverse these astrocyte changes, offering mechanistic insight into neuroinflammation and opioid tolerance.

• Targeting PID1 Reprograms Tumor Macrophages via Cholesterol

  2026-07-27

  This study uncovers how PID1 deficiency in tumor-associated macrophages drives oxysterol production, reprogramming these cells toward an antitumor phenotype by modulating cholesterol metabolism. The findings highlight PID1 as a promising immunometabolic target for enhancing antitumor immunity and suggest new strategies for manipulating cholesterol-driven cell fate in the tumor microenvironment.

• FAST Enables Food-Grade Nanoparticles for Nutraceutical Deli

  2026-07-26

  This study introduces Facilitated Self-Assembling Technology (FAST) as a food-grade approach for producing stable, bioavailable nutraceutical nanoparticles. The method eliminates surfactants and organic solvents, offering scalable, regulatory-compliant solutions for oral supplement delivery.

• Differential FGF and Shh Signaling in Penile Development Mod

  2026-07-25

  Wang and Zheng’s 2025 study reveals how divergent expression of Shh, Fgf10, and Fgfr2 governs distinct prepuce and urethral groove formation in guinea pigs versus mice. This comparative approach advances understanding of mammalian penile morphogenesis, with implications for refining models of human urogenital development.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-07-24

  Leverage 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine as a robust, DMSO-soluble α2-adrenergic receptor agonist for immune rejection modulation and osteosarcoma recurrence research. This guide unpacks experimental workflows, troubleshooting, and the translational impact of recent innovations in selective receptor signaling.

• Selective IRAP Inhibitors: Insights from Bestatin Derivative

  2026-07-24

  This study introduces highly selective, nanomolar inhibitors of insulin-regulated aminopeptidase (IRAP) based on α-hydroxy-β-amino acid derivatives of Bestatin (Ubenimex). The work delivers new synthetic strategies and structural insights, deepening the toolkit for probing M1 aminopeptidases in immunology and cancer research.

• SOAT1 as a Target in PHMG-Induced Pulmonary Fibrosis: Mechan

  2026-07-23

  This study uncovers sterol O-acyltransferase 1 (SOAT1) as a central mediator in the development of pulmonary fibrosis following exposure to polyhexamethylene guanidine (PHMG). By linking SOAT1 upregulation to disrupted cholesterol homeostasis and impaired lipophagy in alveolar macrophages, the work opens new avenues for therapeutic intervention and the study of cholesterol metabolism in fibrotic lung disease.

• PID1-Driven Oxysterol Pathways Reprogram Macrophage Immunity

  2026-07-23

  The referenced study uncovers how targeting PID1 in tumor-associated macrophages redirects cholesterol metabolism, generating specific oxysterols that shift macrophages toward an antitumor phenotype. This immunometabolic reprogramming enhances T cell-mediated tumor surveillance, offering a promising avenue for cancer immunotherapy.

• SCH772984: Precision ERK1/2 Inhibition and Tumor Radiosensit

  2026-07-22

  Explore how the potent ERK1/2 inhibitor SCH772984 advances cancer research by enabling targeted MAPK/ERK pathway inhibition, with a unique focus on radiosensitization strategies and tumor microenvironment interplay. Learn how this compound offers new perspectives for overcoming radioresistance in challenging tumor models.

8077 records 6/539 page Previous Next First page 上5页 678910 下5页 Last page